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The genetic analysis of common neurological disorders will
be a difficult and protracted endeavour. Genetics is only
one of many disciplines that will be required but it has
already thrown considerable light on the aetiology of
several major neurological disorders through the analysis
of rare inherited subgroups. The identification of individual
susceptibility genes with variants of smaller effect will be
more difficult but there is no sharp demarcation between
large and small genetic effects, so that many new and
important insights will emerge using existing and new
technologies. The availability of improved neuroimaging,
better animal models of disease and new genetic tools,
such as high-throughput gene chips, expression
microarrays and proteomics, are extending the range of
traditional genetic mapping tools. Finally, an
understanding of the genetic and epigenetic mechanisms
that restrain the differentiation and integration of human
neural stem cells into mature neuronal networks could have
a major impact on clinical practice. These approaches will
be illustrated in the context of Alzheimer disease, Parkinson
disease and synucleinopathies, tauopathies, amyotrophic
lateral sclerosis and stroke.
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T
he sequencing of the human genome sig-
nalled a major shift in the Human Genome
Project from gene discovery in monogenic
disorders towards the ‘‘post genome challenge’’
of gene characterisation and the genetic analysis
of complex disorders. This change was largely
driven by the increasing facility of gene identi-
fication, which led to the identification of .1200
predominantly Mendelian disease genes. An
important conceptual development was the
common disease/common variant (CD/CV)
hypothesis as a model for complex disorders1 2
(see Appendix A, Human genetic variation). This
model proposed that the genetic basis of com-
mon, genetically complex disorders is principally
due to genetic variants that are common in the
population. In contrast, the common disease/rare
variant (CD/RV) model argued that in complex
disorders there is a significant contribution from
rare variants, which include most of those with
the most significant individual effects.3 4
Although the debate continues, the heritability
of a complex trait almost certainly results from
both common and rare variants. One estimate,
based on more than two decades of research on
such traits in the experimentally tractable
organism Drosophila melanogaster, suggested that
between one third and two thirds of the typical
variation in a complex trait, with at least some
effect on reproductive fitness, results from rare
variants with adverse effects.4 The remainder is
due to common variants, many of them with
opposite effects on different traits (some bene-
ficial, others detrimental) allowing them to be
maintained in the population. The motivation for
finding common variants is currently greater
than for finding rare variants, for three main
reasons. First, they provide potential mechanistic
insights; second, they are easier to identify than
rare variants; third, and most important, they
may be of public health importance and allow
identification of subpopulations at increased risk
of disease.5
The success in finding both common and rare
genetic variants influencing susceptibility to
Alzheimer disease (see below) shows that both
CD/CV and CD/RV models are ‘‘correct’’, but it is
a matter of debate as to which will provide the
most useful insights. This is perhaps the biggest
issue at stake, since the majority of complex
traits are polygenic—resulting from the com-
bined action of many different genes, in combi-
nation with often proportionately greater
environmental effects. In addition, recent evi-
dence suggests that interaction effects—gene-
gene and gene-environment—are common, even
in experimental organisms where genotype and
environment are well controlled.6
The methods currently being used to unravel
the genetics of common neurological disorders,
such as Alzheimer disease and stroke, are
essentially the same as those used in the early
phase of the Human Genome Project, namely
low resolution genetic mapping by linkage
analysis in families with multiple affected
individuals, followed by high resolution mapping
using case-control association studies. However,
increasing emphasis is being placed on the latter,
fuelled by technological advances using single
nucleotide polymorphism (SNP) chips (see
Appendix A). However, the large scale use of
candidate gene association studies has led to a
serious problem, with many unreplicated and, in
many cases, spurious associations being pub-
lished. As an example, out of 127 candidate gene
Abbreviations: ALS, amyotrophic lateral sclerosis; APP,
amyloid b protein precursor; ASPs, affected sib pairs;
CD/CV, common disease/common variant; CD/RV,
common disease/rare variant; CSF, cerebral spinal fluid;
FAD, familial Alzheimer disease; FPD, familial Parkinson
disease; FTD, fronto-temporal lobe dementia; IBD,
identical by descent; LD, linkage disequilibrium; MS,
multiple sclerosis; NFD, neurofibrillary degeneration;
PHF, paired helical filament; QT, quantitative trait; SN,
substantia nigra; SNP, single nucleotide polymorphism;
SOD1, superoxide dismutase 1
623
www.jnnp.com
associations with Alzheimer disease reported in a single year,
only three were found to have been replicated in three or
more independent studies.8
A number of principles which have emerged to guide
researchers through the maze of complex genetic disorders
are discussed below.
GUIDING PRINCIPLES
Large sample sizes
Most individual genetic effects on complex traits or diseases
are small, emphasising the need for large sample sizes to
reliably detect them.9 Very few genes are capable of exerting
large effects, but many genes can exert small marginal
effects. A widely accepted model for the distribution of effect
sizes of genetic variants influencing complex traits is an L
shaped distribution—many genes with variants showing
small and peripheral effects on disease (both rare and
common) and a smaller number with variants showing
moderate to large effects (which tend to be rare).4 The effect
of individual variants will therefore often be obscured by
those of other genes and by large environmental and
interaction effects.
Quantitatively varying intermediate disease
endpoints
Quantitative traits (QTs) which influence disease risk are
used whenever possible to increase study power. In a recent
review, it was commented that ‘‘studies using a single clinical
endpoint are akin to a shot at the moon’’, and compare
unfavourably with studies focusing on genetically and
physiologically simpler intermediate traits.5 All individuals
with QT information are informative in genetic mapping
studies, in contrast to studies focusing on disease, where
most of the power comes from the comparatively few affected
individuals. It has been difficult to find useful QTs in
neurological disorders, compared with cardiovascular or
metabolic diseases. The use of disease age of onset or
severity, plasma amyloid b42 in Alzheimer disease, well
validated questionnaires, and structural brain imaging may
facilitate this process.
Ascertainment strategies
It is relatively easy to study ‘‘typical’’ patients with disease,
but other ascertainment schemes are more powerful.
Families of individuals with complex disorders do not
generally have multiple affected members, since the inci-
dence in relatives declines exponentially with decreasing
relationship to the proband, as expected under a polygenic
model. The identification of individuals at the extremes of the
QT distribution is helpful in contributing to study power.
Extreme individuals may show large genetic effects, without
necessarily developing overt disease (for example, because
they lack other risk factors). Screening of large samples may
therefore be required to detect such extreme individuals. For
example, a study of personality traits targeted 88 000
individuals to fill in a postal questionnaire, which identified
over 34 000 sib pairs including many with extreme or
contrasting trait values. A genetic linkage analysis of extreme
or discordant sib pairs led to the identification of several
significant linkage peaks.10 Similarly, the ascertainment of
rare individuals with early onset Parkinson disease was
necessary for the identification of a major gene (DJ-1)
causing this disorder.11
Genetic linkage and case-control association designs
These two methods form the core of the genetic mapping
effort. Linkage analysis is carried out using extended or small
nuclear families (for example, affected sib pairs) (fig 1). The
term ‘‘genetic linkage’’ refers to the finding of an association
between disease and genetic marker within each of a series of
families containing two or more affected individuals, after
carrying out a whole genome scan. The latter involves
genotyping many ‘‘genetic markers’’—variant sites unrelated
to gene function which show common variation in the
general population—situated at regular intervals throughout
the genome (see Appendix B, Genetic linkage and association
6
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Figure 1 The principles underlying genetic linkage analysis of a common neurological disorder. (A) Affected sib pairs (ASPs) are first genotyped for
several hundred genetic markers. For late onset disorders the parents are usually unavailable, but allele sharing between ASPs can still be inferred. In
the absence of linkage, the extent of genetic marker allele (M1–4) sharing between ASPs is zero, one, or two alleles shared (identical by descent or IBD)
as a result of common ancestry. This is expected to occur 25% (no sharing), 50% (one allele shared), or 25% (both alleles shared) of the time, under the
null hypothesis of no linkage (shared alleles are shaded in grey). In the presence of linkage, there is an increase in allele sharing over the null
hypothesis, as shown. This method is robust when the precise mode of inheritance is unknown. Large numbers of ASPs (for example, 500–1000) are
often required to accumulate significant evidence of linkage to a common disorder. Affected individuals are shown as filled boxes (males) or circles
(females) and unaffected individuals are unfilled. (B) Linkage to a late onset disorder may vary according to age of onset. These LOD score data are
from Hall et al62 who reported stronger evidence for linkage to the BRCA1 gene on chromosome 17 in early compared with late onset familial breast
cancer families. The LOD score is the log10 of the likelihood ratio, in which the probability of linkage at a specified genetic distance is compared with
the likelihood under the null hypothesis of no linkage. A likelihood ratio of 1000 (LOD score 3) corresponds to significant linkage (p-value,0.05) for a
monogenic disorder while a LOD score just over 3 is significant for a complex disorder. A LOD score just over 3 is significant for a complex disorder.
The cumulative LOD scores are shown for all families in which the mean age of onset is less than or equal to the age shown on the x axis.
624 Wright
www.jnnp.com
Figure 2 (A) Genetic fine mapping using association studies. Genomic regions shared IBD are shown in black. (B) Allelic association between
Alzheimer disease and SNPs across the region flanking the APOE gene on chromosome 19.63 As cases are only very distantly related, the region of
shared genome is greatest within ,40 kb of APOE and falls off steeply beyond this, impling a very dense genome scan would have been required to
identify APOE. The association was originally identified by genetic linkage to a broad region on chromosome 19q followed by candidate gene
association studies. (C) Linkage disequilibrium (LD) map of the DPP10 gene associated with asthma64 showing regions that are associated or in LD with
each other as a result of non-random association between pairs of markers. The chromosomal region runs from left to right on the x axis at the bottom
of the figure. The strength of association to asthma (red) and the QT immunoglobulin E levels (loge IgE) (yellow) is plotted as 2log(P) against position.
The markers showing strongest association correspond to the highest peaks. The graph is superimposed on the distribution of LD between markers
(measured as D9), which are colour coded and plotted at the marker locations with red (high LD) and dark blue (low LD) at opposite ends of the scale.
The four initial exons of the causal DPP10 gene are shown as white bars.
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analyses). If successful, genetic linkage can identify a large
genomic region, often containing several hundred genes, in
which the disease gene is sought. Linkage disequilibrium
(LD) implies non-random association between a pair of
markers. This is common for markers that are located close to
one another and can occur for several different reasons. The
presence of LD between SNP markers makes it possible to
infer the location of a disease gene that is in LD with a
genotyped SNP. Fine mapping is carried out using the more
familiar case-control association study design (fig 2) in which
excess marker sharing is sought within cases compared to
controls, following a more dense marker genotyping effort
within the identified region. In fine mapping, a broad region
of genetic linkage, often containing about 100 genes, is
narrowed by carrying out dense SNP marker genotyping
across the region in cases and controls. This identifies small
shared ancestral regions that are associated either with cases
or controls. Since the common ancestor is remote, genomic
regions that are shared IBD (shown in black in fig 2) become
progressively smaller over successive generations as a result
of recombination. The number of genes in the identified
region of association now contains a finite number of
candidate genes which can be analysed for sequence
variation.
Choice of study population
Modern urban populations are often extremely diverse and
are far from ideal for gene mapping studies because of
genetic heterogeneity.12 However, there is a trade off between
obtaining large well characterised study cohorts, which are
generally available in urban contexts, and smaller but more
homogeneous cohorts from less diverse population groups.
The Icelandic population was chosen to study complex
diseases to minimise both genetic and environmental
heterogeneity, which led to the discovery of several suscept-
ibility genes, including the PDE4D gene in stroke (see
below).13
Choice of research strategy
The research strategy should be specifically designed to
answer the question posed. If the aim is to identify common
variants with predominantly small genetic effects on a
categorical endpoint, such as disease, a broadly based
candidate gene screening approach may be appropriate,
using common genetic variants (SNPs) (see Appendix A,
Human genetic variation) and a hierarchical case-control
strategy. For example, a moderate number of cases (for
example, n=500) and matched controls could be system-
atically screened for association between disease and
candidate gene SNPs (at an appropriate density per gene).
Candidate genes could be selected on the basis of (a)
expression within a tissue of interest (for example, hippo-
campus or substantia nigra), (b) functional criteria, such as
membership of a known disease pathway, or (c) localisation
to an implicated chromosomal region, on the basis of
previous genetic linkage studies. Positive associations could
then be followed up using an independent and preferably
larger cohort, to eliminate false positives. Alternatively, if the
goal is to identify rarer genetic variants of intermediate effect,
the strategy could be quite different. A genetic linkage
analysis using a large set of families segregating for a QT or
disease would be an appropriate initial strategy, as used to
identify the chromosomal locations of the APOE, aT-catenin,
and GST01 genes (see below). Fine mapping could follow
using a case-control association study, and a dense set of
SNPs confined to the implicated region(s) (fig 2).
Nature of disease susceptibili ty variants
Susceptibility genes in complex diseases are often expressed
in a wide range of tissues and may contain only subtle
variants or combinations of variants, some or all of which lie
outside protein coding sites. This makes identification of
susceptibility variants difficult. Overall, about 5% of the
human genome has functional significance and so is
potentially involved in disease.14 About 1.5% of the genome
contains the protein or RNA coding regions of the 20 000–
30 000 human genes, in which lie an estimated 20 000
coding or cSNPs.5 These represent an important initial target
for whole genome association studies. Firstly, they are more
likely to influence disease than non-coding SNPs and,
secondly, a genome scan could be carried out using
substantially fewer markers than the estimated 600 000–
1 000 000 non-coding SNPs required to provide coverage of
the entire genome.5 A further 1% of the human genome lies
within genes and is transcribed but is not translated into
protein. Finally, an additional 2.5% of the genome lies
outside of the genes altogether but is conserved across
species, suggesting that these regions also have functional
importance. Proving that such subtle non-coding variants
influence a complex disease is difficult. In monogenic
disorders, the situation is quite different, with 99% of
mutations occurring in protein coding or splice sites, and
only 1% within non-coding regulatory regions.15 The best
evidence that a gene influences disease susceptibility comes
from the identification of several different genetic variants
within its coding or splice sites in different affected (or
extreme QT value) individuals, coupled with the demonstra-
tion that variants affect gene function and show relevant
tissue expression.
APPLICATIONS TO CLINICAL NEUROLOGY
Alzheimer disease
Alzheimer disease provides an excellent paradigm for the
genetic basis of a complex disorder, with contributions from
both common modifier genes and rare variants of large
effect.16 Heritability estimates in Alzheimer disease are in the
region of 60%,17 suggesting that genetic variation plays a
significant role in the disease process. However, the major
insights into disease mechanisms to date have come from
mutations in genes that are so rare that they make essentially
no contribution to the heritability of the disease as a whole.
One of the best paradigms for the CD/CV hypothesis was
the discovery of common variants in the APOE gene which
influence susceptibility to Alzheimer disease. There are three
common APOE alleles (E2, E3, E4) in human populations,
resulting from differences at two amino acid residues
(residues 112, 158).18 Associations between the E4 allele,
which is present in about one third of Caucasians, and
Alzheimer disease have been widely confirmed, but associa-
tions have also been found with several other disorders—the
Lewy body variant of Alzheimer disease, Parkinson disease,
susceptibility to herpes simplex virus infection, poor recovery
from head injury, intracerebral haemorrhage, and elective
cardiac bypass surgery.19 A protective effect of the E2 allele in
Alzheimer disease has also been reported. APOE is the
primary cholesterol transporter in the brain and is a
component of both amyloid (senile) plaques and neuro-
fibrillary tangles. The mechanism for the effects of APOE
isoforms on brain damage and dementia is unclear, although
transgenic ApoE deficient mice (Apoe2/2) engineered to
express a human APOE E4 allele showed age related spatial
learning and memory defects, in contrast to Apoe2/2 controls
or mice carrying the E3 allele.20 Lipid carrying apoE3 binds
amyloid b (Ab) peptide, the major constituent of amyloid
plaques, with 20-fold higher affinity than lipidated apoE4,
which may enhance the clearance of Ab.21 The close
relationship between APOE and Alzheimer disease risk is
highlighted by the finding that transgenic mice overexpres-
sing familial Alzheimer disease mutations on an Apoe2/2 null
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background show very little Ab amyloid deposition, com-
pared with those on a normal (wildtype) Apoe+/+ back-
ground.22 This suggests that APOE is essential for Ab
deposition in transgenic models of familial Alzheimer disease
(FAD). It remains unclear whether this effect is mediated by
increased formation or decreased clearance of Ab amyloid.
The effect of the APOE E4 allele is dosage dependent, so
that carriers of a single E4 copy have a twofold increased risk
of Alzheimer disease compared with a fivefold risk for
homozygotes with two copies. The E4 allele appears to be a
disease modifier, exerting its effect on disease risk by
influencing age of onset in both Alzheimer disease and
Parkinson disease, rather than disease risk per se. Despite the
relatively large effects of these variants, the use of APOE
genotype information in disease prediction remains limited,
since its diagnostic sensitivity is only 0.65 and specificity 0.68,
compared with clinical diagnosis, which has a reported
sensitivity of 0.93 and specificity of 0.55.23
A number of Alzheimer disease modifier loci have recently
been proposed, none of which have yet been consistently
replicated, but they illustrate some of the approaches taken
and difficulties encountered. The glutathione-S-transferase
(GST01) gene was proposed to be a determinant of age of
onset, here used as a QT, in both Alzheimer disease and
Parkinson disease.24 GST01 is widely expressed and is
thought to be concerned with the biotransformation of
compounds such as free radicals and interleukin-1b. The
gene was identified by narrowing the number of genes in the
large region of chromosome 10 implicated by linkage analysis
from several hundred genes to only four, on the basis that
only these genes showed altered expression in the hippo-
campus of Alzheimer disease compared with control subjects.
This is an interesting but potentially misleading assumption.
Using a case-control strategy, and large sample sizes, the
authors found a significant association with one of the three
genes, GST01.24 One of the common variants analysed, SNP7,
was associated with the substitution of aspartic acid for
alanine at residue 140 (Ala140Asp) in the GST01 product.
However, since about 90% of the population carry one or two
copies of this early onset ‘‘risk’’ allele (Ala140), it remains
unclear how much of the original linkage signal is explained
by this (and the associated SNP9) variant, or how useful the
resultant mechanistic insights will be.
The identification of another proposed genetic modifier in
Alzheimer disease followed the discovery of an association
between the insulin degrading enzyme (IDE) gene and
Alzheimer disease itself,25 26 age at onset in both Alzheimer
and Parkinson disease,27 and plasma amyloid Ab42, some-
times used as a QT risk factor for Alzheimer disease.28–30 The
Ab42 peptide is a secreted cleavage product of the amyloid b
protein precursor (APP), which is strongly expressed in brain
and cerebral spinal fluid (CSF). Ab42 is present in CSF at 50
times its concentration in plasma, but, in a longitudinal
study, individuals who developed Alzheimer disease showed
higher levels of plasma Ab42, suggesting its use as a surrogate
for brain Ab42 production. Plasma Ab42 is elevated in
individuals with familial late onset Alzheimer disease, in
early onset FAD, and in Down syndrome (since the APP gene
is carried on chromosome 21). It remains unclear which
variants in or close to the IDE gene are directly concerned
with Alzheimer disease risk, age of onset, and plasma Ab42
levels. IDE is an interesting candidate gene since it has been
shown to regulate Ab42 levels in brain neurons and microglial
cells.29 30 Increased degradation of Ab42 by transgenic mice
overexpressing IDE or another Ab-degrading protease,
neprilysin, slows Ab42 deposition and reduces Alzheimer-like
pathology in mouse models of FAD.31
The most significant advances in the genetics of Alzheimer
disease and Parkinson disease to date have come not from
the identification of the common variants discussed above,
but from the study of genes which have virtually no role in
common forms of these disorders. Mutations in three genes
account for about half of all cases of FAD,32 which is an
extremely rare disease, with fewer than 200 confirmed FAD
families worldwide, compared with an estimated 4–5 million
Alzheimer disease individuals in the USA alone.33 FAD is
clinically and pathologically indistinguishable from
Alzheimer disease except for age of onset. The most common
cause is a mutation in the presenilin-1 (PS1) gene, which is
found in about half of all FAD families. Mutations in the
related presenilin-2 (PS2) gene and in the APP gene account
for ,1% and ,5% of FAD families, respectively.32 Mutations
in all three genes give rise to increased Ab42 formation since
the presenilins form part of a protein complex concerned
with the processing and release of the neurotoxic Ab42
peptide from APP.16 Mutations in the APP and PS1 genes give
rise to a fully penetrant autosomal dominant disorder with
onset in the age range 35–55 years, while PS2 mutations are
more variable, often showing later onset (age range 40–
85 years) and occasional non-penetrance.
The importance of these rare mutations lies in the
identification of a pathogenetic pathway, involving the
endoproteolytic cleavage of the transmembrane APP protein
by the enzymes BACE1 and the c-secretase complex.16 The
common factor in Alzheimer disease arising from Down
syndrome and mutations in the APP, PS1, and PS2 genes is an
excess production of the neurotoxic Ab42 peptide or an
increased ratio of Ab42 to the less toxic Ab40 peptide.
Paradoxically, the pathogenetic sequence in the transition
from old age through mild cognitive impairment to
Alzheimer disease emphases the role of neurofibrillary
degeneration (NFD), associated with paired helical filament
(PHF)-tau deposition, rather than amyloid plaque forma-
tion.34 35 Amyloid deposits are deposited randomly through-
out the entire cerebral cortex, and tend to appear subsequent
to NFD and PHF-tau deposits in any one region. NFD
progresses hierarchically along specific neuronal pathways
(starting in the trans-entorhinal cortex and progressing to
the temporal cortex), suggesting a specific vulnerability in
these pathways. It has been suggested that this vulnerability
may be enhanced in the presence of increased Ab42
formation, which can result from genetic mutations or
environmental events such as head injury or stroke. There
is an apparent progression in the extent of both NFD and
amyloid deposits from normal ageing to Alzheimer disease.
For example, in one study, 100% of individuals over age 75
showed NFD in the hippocampus, often in the absence of
amyloid plaques or dementia, whereas those with Alzheimer
disease (by definition) also have both significant neuronal
loss and amyloid plaques.34
TAUOPATHIES
The discovery of mutations in the Tau gene in a subset of
patients with fronto-temporal lobe dementia (FTD) linked to
chromosome 17 (FTDP-17) throws further light on Alzheimer
disease mechanisms.36 FTD is an early onset (,65 years)
disorder associated with prominent frontal lobe symptoms,
such as behavioural disinhibition, with fronto-temporal
atrophy due to neuronal loss, spongiform degeneration, and
gliosis, sometimes extending to the substantia nigra (SN),
amygdala, and spinal cord. Clinical presentation can be
accordingly varied. There are no amyloid or Lewy bodies and
a small proportion of patients have Tau gene mutations.37 Tau
is a phosphoprotein expressed in peripheral and central
nervous systems, predominantly in neurons, where it is
associated with axons and concerned with the microtubule
binding and assembly that is necessary for axoplasmic
transport.37 Hyperphosphorylated Tau deposits are associated
Neurogenetics II: complex disorders 627
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with PHF and the NFD found in Alzheimer disease. In FTDP-
17, both loss of function mutations and mis-expression of the
Tau gene, which is normally processed into different iso-
forms, are found. The precise disease sequence and mechan-
ism remains unclear, but amyloid Ab42 overexpression
appears to exacerbate Tau pathology. One possibility is that
APP mis-processing in Alzheimer disease leads to post-
translational modification of the Tau protein and subsequent
neurodegeneration. The observation that amyloid deposition
follows rather than precedes Tau mis-processing could
however also be explained by the proposal that Ab42
neurotoxicity results from formation of the more toxic
soluble protofibrils rather than the later appearing insoluble
fibrillar aggregates.38
Parkinson disease and synucleinopathies
The presence of neuronal loss and insoluble aggregates of a-
synuclein, called Lewy bodies, in the SN are the major
pathological features of Parkinson disease.39 Surprisingly, the
prevalence of SN Lewy bodies in the general population is ten
times greater than the prevalence of Parkinson disease, but
there appears to be a threshold, so that those with SN
neuronal loss exceeding about 60% show symptoms of
Parkinson disease. This may be because in disorders of
protein aggregation, the characteristic aggregates are actually
protective but when present in large numbers are indicative
of a more sinister underlying process or extent of disease.
Post mortem studies show that SN cell loss in the normal
population follows an exponential distribution, with 4.4% of
cells lost per decade.40 In contrast, cell loss in Parkinson
disease appears to occur ten times faster, at a rate of 45% per
decade, with onset about 4–5 years before symptomatic
disease.40 Lewy bodies are also a prominent feature in other
neurological disorders—dementia with Lewy bodies, multiple
system atrophy, Down syndrome, and neurodegeneration
with brain iron accumulation I.41 Ten genes have been
mapped by genetic linkage to rare monogenic forms of
familial Parkinson disease (FPD), four of which have been
isolated: the a-synuclein (SNCA), ubiquitin C-terminal
hydrolase like 1 (UCH-L1), parkin (PRKN), and DJ-1 genes.42
These have again provided mechanistic insights into common
forms of Parkinson disease. Firstly, mutations in the a-
synuclein gene result in early onset autosomal dominant
FPD.43 Autosomal dominant FPD families showing triplica-
tion or duplication of the SNCA gene present FPD symptoms
in the fourth and fifth decades respectively, implying that
overexpression even of normal a-synuclein is sufficient to
cause disease. Genetic variability in the SNCA promoter
region was associated with increased risk of sporadic
Parkinson disease. This is consistent with the possibility
that, like overexpression of Ab42 in Alzheimer disease and
Down syndrome, increased formation of normal a-synuclein
can be disease causing.
Mutation in the PRKN gene causes juvenile or early adult
(,45 years) onset autosomal recessive PD.44 Complete loss of
parkin due to homozygous deletion of the PRKN gene is
associated with severe loss of dopaminergic neurons in the
SN and locus coeruleus but a notable absence of Lewy bodies.
Some amino acid changing (missense) mutations in PRKN do
show both Lewy bodies and abnormal tau deposits (NFD),
suggesting a possible gain of function. One explanation is
that since parkin is an E3 ubiquitin ligase, it is a component
of the ubiquitin proteasome system, which may be required
to produce Lewy bodies. The ubiquitin protease system is
involved with the degradation of misfolded proteins, some of
which—such as a-synuclein and perhaps some types of
mutant parkin itself—can give rise to aggregation and
neurodegeneration. The importance of this pathway is
reinforced by the finding of mutations in the UCHL1 gene,
coding for ubiquitin carboxy-terminal hydrolase L1, one of
the most abundant proteins in the brain, in rare autosomal
dominant FPD families.45 The UCHL1 enzyme is found in
Lewy bodies and is also concerned with protein degradation.
UCHL1 mutations lead to accumulation of a-synuclein in
cells and may influence susceptibility to Parkinson disease by
altering the balance of ubiquitin hydrolase and ligase
activities, both of which are present in UCHL1, impairing
the degradation of a-synuclein.46
DJ-1 is another component of the ubiquitin/proteasome
protein degradation pathway which is mutated in a rare
autosomal recessive form of early onset Parkinson disease.11
The gene was identified by genetic linkage analysis in a large
inbred Dutch community in which the mutant gene appeared
to be more common as a result of a founder effect and
cultural isolation of this population. Since both Parkin and
DJ-1 are components of the ubiquitin proteasome pathway,
and are concerned with the degradation of fibrillogenic
proteins within the SN, these rare genes have again identified
an important pathogenetic pathway in all forms of Parkinson
disease, despite making essentially no contribution to
heritability in the common form.
Amyotrophic lateral sclerosis (ALS)
ALS is a progressive disease associated with degeneration of
motor neurons in the brain stem and spinal cord. Surviving
neurons contain inclusions of neurofilament components
and ubiquitin. It is generally sporadic but rare familial forms
of ALS occur in about 10% of patients, about 20% of which
are associated with missense mutations in the cytoplasmic
enzyme Cu/Zn superoxide dismutase 1 (SOD1), which is also
present in the inclusions.47 48 It is unclear whether the disease
results from a gain of function, such as protofibril toxicity, or
loss of function and oxidative stress. SOD1 catalyses the
dismutation of the superoxide radical to form hydrogen
peroxide and oxygen. One possibility is that an oxidising
environment (due to reduced SOD1 activity) causes protein
instability, aggregation, and neurotoxicity, since mutant
SOD1 aggregates have been seen under such conditions.
Cerebrovascular disease and stroke
Stroke is a heterogeneous group of ischaemic and, less
commonly, haemorrhagic disorders, which are associated
with atherosclerosis of large blood vessels or occlusion of
small penetrating arteries in the brain. All forms of stroke
share common risk factors, including hypertension, hyperli-
pidaemia, diabetes, and smoking. Family history is an
independent risk factor, suggesting that genetic factors may
contribute to susceptibility.49 Genetic linkage analysis of
Icelandic families segregating for stroke provided the initial
evidence for a susceptibility gene on chromosome 5. Fine
mapping was carried out in a case-control study of 864
affected individuals from the Icelandic population and 908
controls, using 98 markers spanning the implicated chromo-
somal region. A broad definition of stroke was employed,
including both cardiogenic and carotid stroke, and common
variants within the phosphodiesterase 4D (PDE4D) gene were
found to be associated.13 The highest risk haplotype (present
in 9% of controls) conferred a twofold relative risk. A
protective haplotype (present in 21% of controls) was also
identified, with a relative risk of 0.7. However, none of the
associated variants were present in protein coding or gene
splicing regions, suggesting that the identified and/or
associated variants affect gene regulation (such as expression
level) rather than having a direct functional effect on the
protein. Some protein isoforms associated with the risk
haplotype may be expressed at a lower level in patients than
in controls. The PDE4D risk haplotype has an effect that is
largely independent of known risk factors. The PDE4D gene
encodes a cyclic nucleotide phosphodiesterase which
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degrades cyclic AMP and regulates signal transduction in a
wide variety of cells. One possibility is that PDE4D variants
cause low cyclic AMP levels, increasing the tendency for
proliferation and migration of vascular smooth muscle cells,
although similar effects in the immune system are also
possible. These findings and their pathogenic significance
remain to be confirmed and elucidated.
A similar approach led to the identification of another
gene, ALOX5AP, coding for 5-lipoxygenase activating protein,
in which certain common haplotypes double the risk of both
stroke and myocardial infarction.50 The initial finding was a
suggestive linkage to a region of chromosome 13 in a series of
296 Icelandic families with multiple affected members. A
case-control association study was carried out using a high
density of markers across the implicated region (containing
40 known genes) which led to the identification of the
ALOX5AP susceptibility gene. This was confirmed in a UK
population, although the associated haplotype was different.
The individual or combination of variants associated with
disease risk remain to be identified. ALOX5AP and 5-
lipoxygenase together convert unesterified arachidonic acid
to the leukotriene LTA4, which is further converted to LTB4
or LTC4.50 These are important proinflammatory mediators
which are active in macrophages and leukocytes invading
atherosclerotic lesions.
NEW TECHNOLOGIES
Increasing access to powerful new technologies will facilitate
the discovery of genetic influences in neurological disorders.
Perhaps the most important ones are those concerned with
refining the clinical phenotype, such as brain imaging
techniques, and developing quantitative intermediate disease
endpoints. The goal of reliably defining simpler phenotypes
than disease itself, such as carotid intima media thickness,
instead of more complex and categorical traits such as stroke,
is particularly important. Other enabling technologies are
allowing high throughput analysis of genes and their
products in health and disease, which is beginning to
influence neurological research. The new technologies are
discussed below.
Microarrays
High density arrays of DNA sequences, such as SNP alleles or
expressed gene sequences (cDNA), can be immobilised on
miniaturised grids (chips), in order to perform large scale
screening experiments.51 For example, the messenger RNA
(mRNA) from both normal and diseased neurological tissues
can be extracted, converted to DNA (cDNA) and labelled
prior to hybridisation to the chip, in order to identify genes
that are differentially expressed in disease. Alternatively,
genomic DNA from an individual could be labelled and
hybridised to an SNP chip containing tens or hundreds of
thousands of SNP variants, to search for a disease associa-
tion. Finally, if a candidate gene for a disease has been
mapped to a specific genomic region containing a few
hundred genes, it may be useful to know which genes from
that region are expressed in the diseased region using
microarrays.
This technology has been used to investigate neurological
disorders.52 In one study, cDNA microarrays containing
18 000 genes were hybridised to cDNA from hippocampal
CA1 neurons with or without neurofibrillary tangles in
Alzheimer and control brains.53 Similarly, prefrontal cortex
from schizophrenic versus control brains was screened using
arrays containing 7000 genes to detect differences in gene
expression, which showed decreased expression of genes
regulating presynaptic function.54 It is important to confirm
changes in gene expression shown by microarray using
other methods, such as immunohistochemistry, in situ
hybridisation, or reverse transcription polymerase chain
reaction. A final example is the use of microarrays in the
transcriptional analysis of brain plaques from multiple
sclerosis (MS) samples compared with control brain sam-
ples.55 This type of study identified osteopontin (OPN) gene
expression exclusively in MS plaques, which led to the
proposal that this proinflammatory molecule is expressed by
infiltrating T lymphocytes, microglia, and macrophages, and
promotes damage to the myelin sheath as a result of an
autoimmune process. Polymorphisms in OPN also appear to
influence the disease course.56 57
Proteomics
Gene expression profiles provide little information on genetic
variation and may give misleading information on the
function or expression of their protein products. The
proteome, which is the sum of all expressed proteins in a
tissue or cell, is regulated at different levels, including
synthesis, degradation, and a wide variety of post-transla-
tional modifications, such as phosphorylation. The abun-
dance of the mRNA coding for a specific protein may be
poorly correlated with protein abundance. However, the
variety and different physico-chemical properties of proteins
complicates the ‘‘protein chip’’ approach, although the entire
yeast proteome has now been arrayed on a chip. Instead, the
techniques of two-dimensional gel electrophoresis, in-gel
digestion, and peptide identification by microsequencing or
mass spectrometry, are together enabling the high through-
put analysis and identification of unknown proteins dissected
from healthy or diseased tissues. Two-dimensional gel
electrophoresis allows the separation of several hundred
proteins by molecular size and net charge while techniques
such as MALDI-TOF or tandem (q-TOF) mass spectrometry
facilitate their identification.58 For example, over 300 proteins
were identified from subcellular fractions of human frontal
cortex using such an approach.58 Current limitations include
the difficulty of analysing hydrophobic proteins, such as
membrane receptors, and the identification of post-transla-
tional modifications in a high throughput manner. These
techniques however have the potential for refining the
analysis of cells and tissues in neurological disorders.
Firstly, they can provide critical information on the structure
and function of specific proteins, such as disease related post-
translational modifications. Secondly, they can provide an
overview of the collective changes occurring within a brain
region which can help to subdivide and refine molecular
subtypes of disease.
Neural stem cells
There is considerable interest in the possibility of inducing
resident human neural stem cells, that are known to be
present in the subependymal zone and hippocampus, to
differentiate into and replace neurons damaged by ischaemia,
trauma, or neurodegeneration.59–61 This property is retained in
the brains of some simpler non-mammalian vertebrates but
appears to have been progressively lost with the evolution of
increasing brain complexity from amphibians through to
rodents and primates. The precise number of human neural
stem cells is unknown but ,1% of human subependymal
cells display the Ki-67 marker that is associated with a
capacity for cell division.60 In human bone marrow, only
about 1 in 106 cells show the properties of haematopoietic
stem cells. Human neural stem cells display glial astrocyte
but not neuronal markers, although they are able to generate
both neuronal and glial cells in culture. It therefore appears
that there is an inherent resistance of such cells to undergo
neurogenesis in vivo, perhaps because of the need to retain
the complex neuronal networks built up by experience and
learning. The goal of replacing cells from the temporal or
parietal association cortex which are lost in Alzheimer
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disease therefore currently seems remote. The more limited
goal of understanding the restraints on neural differentiation
that limit the neurogenic potential of subependymal neural
stem cells in vivo compared with in vitro may well be
achievable. This knowledge could ultimately lead to replace-
ment of specific motor or sensory neurons serving less
advanced brain functions.
CONCLUSIONS
Genetics is only one of many disciplines that will be required
to elucidate disorders like epilepsy and dementia. However, it
is a very powerful tool for dissecting such complex
phenotypes. Historically, the power of the genetic approach
has come from the analysis of relatively simple and rare
Mendelian disorders which resemble complex traits or
diseases and elucidate key disease mechanisms and path-
ways. This is well illustrated by the analysis of genes
responsible for early onset forms of Alzheimer disease and
Parkinson disease. The identification of individual suscep-
tibility genes with variants of smaller effect is proving more
difficult. The increased availability of animal models of
inherited neurological diseases, and of high throughput gene
based technologies, such as microarrays and proteomic
analyses, extend the range of traditional genetic tools, such
as gene mapping. Finally, an understanding of the genetic
and epigenetic mechanisms that restrain the differentiation
and integration of human neural stem cells into mature
neuronal networks could have a major impact on clinical
practice.
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APPENDIX A
HUMAN GENETIC VARIATION
Humans are on average 99.9% identical, with one variant
base every 1300 base pairs.7 Most of the genetic differences
between any two individuals consist of SNPs, which are
single base changes present in at least 2% of the population
(allele frequency .0.01). There are probably over 10 million
SNPs and an almost unlimited number of rare variants in the
human population.7 Most common variants are extremely
ancient, pre-dating the divergence of human racial groups
.100 000 years ago. They survive in the human genome
because the majority are ‘‘neutral’’ in their effects on
reproductive fitness. They therefore confer no reproductive
advantage or disadvantage. Some common variants have
arisen or become common within more recent times (for
example, ,10 000 years) as a result of selection for some
favourable characteristic. In contrast, genetic variants with
intermediate or large effects on disease are predicted to be at
low population frequency, since they tend to have adverse
effects both on disease related traits and on reproductive
fitness (which are usually correlated).4 Collectively, however,
there are many more rare variants than common ones in the
human population and these are the ones with large
functional effects that contribute most to human
Mendelian diseases. It remains to be seen to what extent
these rather than common variants provide most insights
into common disorders.
APPENDIX B
GENETIC LINKAGE AND ASSOCIATION ANALYSES
A genetic linkage analysis (fig 1A) aims to identify a gene of
moderate effect by scanning the genome with several
hundred evenly spaced genetic markers to find one or more
that segregates with the trait or disease. An association is first
sought between each marker and the trait or disease within
each family. The probability of the observed data, assuming
either linkage or the null hypothesis of no linkage, are
summarised in a LOD score table or graph (fig 1B). In some
late onset disorders, the LOD score declines with age of onset,
indicating that other factors, such as polygenic or environ-
mental influences, obscure the effect of single genes (fig 1B).
Significant evidence of linkage can occur either by chance or
because genetic marker and susceptibility gene are adjacent
to one another on the same chromosome (true genetic
linkage). Different families may have different mutations,
but in linkage analysis it is assumed that these occur
predominantly within a single gene, and account for much
of the variation in disease susceptibility.
A case-control association study compares the frequency of
a single SNP marker or more usually a combination of SNPs
on a single chromosome (SNP haplotype) in cases and
controls (fig 2). An excess of marker alleles or haplotypes in
cases compared with controls may occur by chance or as a
result of genetic association. A true association occurs when
apparently unrelated individuals share a region of the
genome as a result of distant common ancestry (fig 2A). In
order to identify such regions, a high density of genetic
markers is required, which is often restricted to the vicinity of
a linkage peak (fig 2B). Association can occur between a
disease or QT and genetic marker even if the genetic
variant(s) conferring disease susceptibility is not tested
directly, provided it is associated with adjacent (tested)
markers, due to common ancestry (linkage disequilibrium)
(fig 2C). Regions of association between SNP markers are
being defined in the HapMap project, which aims to
determine the most efficient combinations and density of
marker SNPs for disease gene mapping. The aim is to use
sufficient well chosen SNPs so that any untested but disease
associated SNP will still be detectable in an association study,
as a result of its association with adjacent (tested) SNPs
(fig 2C).5
Genetic association methods work well for fine mapping
within a (linkage) defined region, but their use in screening
the entire genome for disease susceptibility genes requires
very high marker densities—in the region of hundreds of
thousands of SNPs, since only a small segment of genome is
shared between distantly related individuals (fig 2A). This
generates many false positive associations. A second problem
is the underlying assumption in association studies that a
significant fraction of the variation in disease susceptibility
results from not only a single gene, but a single variant
within a single gene, making it more restrictive than the
linkage approach. It is however a powerful approach for
identifying common, small effect variants in large population
samples, for example using candidate genes.
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